1-3 of 3
Douglas H. Thamm, VMD
Close
Sort by
Journal Articles

Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma

Olivier Hermine, Ambroise Marçais, MD, Thiago Maciel, J Bagbor, Darius Jagielski, VMD, Nadine Holtermann, VMD, Elena Martinez de Merlo, VMD, Douglas H. Thamm, VMD, Patrice Dubreuil, PhD, Alain Moussy, MBA
Journal: Blood
Blood (2015) 126 (23): 3993.
https://doi.org/10.1182/blood.V126.23.3993.3993
Published: 2015
Journal Articles

GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Has Antitumor Activity Against Naive and Melphalan-Refractory Spontaneous Myeloma in Pet Dogs.

Douglas H. Thamm, VMD, Daniel B. Tumas, DVM, PhD, Hans Reiser, MD, Grushenka H.I. Wolfgang, PhD, Ilene D. Kurzman, EdD, Susan Plaza, DVM, Christie Anderson, DVM, Cecilia Robat, DMV, David M. Vail, DVM, MS
Journal: Blood
Blood (2007) 110 (11): 1508.
https://doi.org/10.1182/blood.V110.11.1508.1508
Published: 2007
Journal Articles

GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Demonstrates Significant Therapeutic Activity Against Spontaneous Non-Hodgkin’s Lymphoma as Modeled in Pet Dogs.

David M. Vail, DVM, Douglas H. Thamm, VMD, Daniel B. Tumas, DVM, Hans Reiser, MD, Adrian S. Ray, PhD, Grushenka H.I. Wolfgang, PhD, Darius Babusis, BA, Ilene D. Kurzman, EdD, Robert Jeraj, PhD, Susan Plaza, DVM, Christie Anderson, DVM, Mackenzie A. Wessel, BS, Cecilia Robat, DVM, Jessica Lawrence, DVM
Journal: Blood
Blood (2007) 110 (11): 1380.
https://doi.org/10.1182/blood.V110.11.1380.1380
Published: 2007